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ABSTRACT
Background Barrett’s oesophagus (BE) is a pre-
malignant condition leading to oesophageal
adenocarcinoma (OAC). Treatment of neoplasia at an
early stage is desirable. Combined endoscopic mucosal
resection (EMR) followed by radiofrequency ablation
(RFA) is an alternative to surgery for patients with BE-
related neoplasia.
Methods We examined prospective data from the UK
registry of patients undergoing RFA/EMR for BE-related
neoplasia from 2008 to 2013. Before RFA, visible lesions
were removed by EMR. Thereafter, patients had RFA 3-
monthly until all BE was ablated or cancer developed
(endpoints). End of treatment biopsies were
recommended at around 12 months from first RFA
treatment or when endpoints were reached. Outcomes
for clearance of dysplasia (CR-D) and BE (CR-IM) at end
of treatment were assessed over two time periods
(2008–2010 and 2011–2013). Durability of successful
treatment and progression to OAC were also evaluated.
Results 508 patients have completed treatment. CR-D
and CR-IM improved significantly between the former
and later time periods, from 77% and 56% to 92% and
83%, respectively (p<0.0001). EMR for visible lesions
prior to RFA increased from 48% to 60% (p=0.013).
Rescue EMR after RFA decreased from 13% to 2%
(p<0.0001). Progression to OAC at 12 months is not
significantly different (3.6% vs 2.1%, p=0.51).
Conclusions Clinical outcomes for BE neoplasia have
improved significantly over the past 6 years with
improved lesion recognition and aggressive resection of
visible lesions before RFA. Despite advances in
technique, the rate of cancer progression remains 2–4%
at 1 year in these high-risk patients.
Trial registration number ISRCTN93069556.
INTRODUCTION
Patients with Barrett’s oesophagus (BE) are at
increased risk of developing oesophageal adenocar-
cinoma (OAC). BE arises in response to chronic
acid reflux and has a population prevalence in the
region of 1.6%.1 The incidence of OAC continues
to rise in the Western world.2–4 Despite advances
in medical care, the prognosis from this disease is
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Significance of this study
What is already known on this subject?
▸ High-grade dysplasia and intramucosal cancer
arising in Barrett’s oesophagus (BE) can carry a
40–60% risk of progressing to oesophageal
adenocarcinoma.
▸ The British Society of Gastroenterology has
recently released guidelines recommending that
patients with BE-related neoplasia and disease
confined to the mucosa (T1a) should be offered
endoscopic therapy as first-line treatment.
▸ The radiofrequency ablation (RFA) registry was
founded in 2008 to audit and monitor the
outcomes of those undergoing minimally
invasive endoscopic therapy.
What are the new findings?
▸ Between 2011 and 2013 there has been a
significant improvement in clinical outcomes for
patients undergoing endoscopic treatment for
BE-related neoplasia.
▸ Reversal of all dysplasia has risen from 77% to
92% at 12 months compared with patients
treated between 2007 and 2010.
▸ Between 2011 and 2013 the progression to
invasive cancer at 12 months was 2.1% and the
calculated cancer risk at almost 34 months is 3%.
▸ Latterly, endoscopic mucosal resection is more
widely used prior to initiating RFA, but the risk
of symptomatic stenosis requiring endoscopic
therapy has not changed over time.
How might it impact on clinical practice in
the foreseeable future?
▸ There is now consensus that first-line treatment
for mucosal neoplasia arising in BE should be
endoscopic therapy.
▸ Lesion recognition and resection prior to RFA are
paramount to successful outcomes in patients
with BE neoplasia. Visible and nodular lesions are
more likely to harbour more advanced neoplasia,
so early resection is key to both definitive staging
and eradication prior to RFA.
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poor with a 5-year survival of 7% in England and Wales.
Although metaplastic BE confers a low risk of progression to
OAC in the region of 0.12–0.40 per year,5–7 the presence of
dysplasia in BE can increase this risk significantly. High-grade
dysplasia (HGD) and intramucosal cancer (IMC) (collectively
referred to as BE-related neoplasia) arising in BE are now gener-
ally believed to carry a 40–60% risk of progressing to OAC.8
The treatment options for patients with BE-related neoplasia
have shifted dramatically over the past few years, from radical
surgery with oesophagectomy towards minimally invasive endo-
scopic therapy.
For many years the preferred strategy for managing these
patients has been either intensive endoscopic surveillance until
cancer develops or surgery with oesophagectomy to cure the
disease. Indeed, in patients undergoing surgery for HGD, more
advanced disease used to be found in 40% of cases,9 although
more recently with better endoscopic imaging this has fallen to
17%.10 Surgical techniques continue to improve and, although
the operative mortality has fallen from as high as 12% in the
1990s,11–13 it remains not insignificant at the present time. Data
from the UK National Oesophago-Gastric Cancer Audit
(NOGCA) in 2012 demonstrated an intraoperative mortality of
2–4% for all patients, although for patients undergoing surgery
for HGD the surgical mortality is lower at 1%.14 In addition, the
subsequent morbidity can be 40%15 and it usually takes at least
9 months before patients return to a normal quality of life.16 17
Given the morbidity and mortality that may be associated
with oesophagectomy, less invasive endoscopic treatment modal-
ities have emerged. The British Society of Gastroenterology
(BSG) has recently released guidelines recommending that
patients with BE-related neoplasia and disease confined to the
mucosa (T1a) should be offered endoscopic therapy as first-line
treatment. It should be offered only in specialist high volume
centres where the expertise and support is in place to carry out
these interventions.18
The rationale for endoscopic therapy is that the risk of distant
metastasis is low.19 20 Once there is submucosal involvement
(T1b disease) this risk is greater (up to 20%), and endoscopic
therapy should no longer be considered curative.21 22 Published
data from limited randomised studies23 have been followed up
by several larger series from prospective studies showing
short-term efficacy and encouraging long-term durability while
maintaining a good safety profile for endoscopic therapy with
radiofrequency ablation (RFA) and endoscopic mucosal resec-
tion (EMR). Real-life data demonstrating the effectiveness of
these therapies in large volume registry populations has again
shown sustained promise.24–26
The aims of the present study were: (1) to assess the long-
term clinical efficacy of RFA/EMR as first-line treatment for
over 500 patients with BE-related neoplasia within the UK regis-
try since its inception in 2008; (2) to establish whether, after
6 years of endoscopic therapy, there has been any change in
clinical outcomes for these patients by comparing patients
treated in the first 3 years of the registry with those treated in
the second 3-year period; and (3) to determine factors that may
be associated with changes in outcome.
METHODS
Inclusion criteria
All patients were referred for consideration of endoscopic man-
agement of dysplastic BE at a specialist centre within the UK
registry. Only men and non-pregnant women over the age of
21 years with no contraindications to endoscopy were consid-
ered. All patients gave written informed consent and agreed to
attend at regular intervals for treatment and surveillance
procedures.
Pretreatment staging
All patients with a diagnosis of BE neoplasia were discussed
within specialist multidisciplinary team (MDT) meetings at
designated centres within the UK Upper GI Cancer Network in
compliance with BSG guidelines. Those diagnosed at smaller
local hospitals were referred on and restaged at the regional spe-
cialist centre performing RFA/EMR.
The registry captures data on all patients treated regionally at
the designated centres. These centres are selected by each
regional cancer network and have the necessary training and
support infrastructure to carry out safe and effective endoscopic
therapy on any patients with BE neoplasia referred to them.
Although the registry protocol describes recommended best
practice, there is invariably variation in treatment and follow-up
intervals depending on local service limitations. The data are
collected through an online anonymised database where demo-
graphic variables are captured together with treatment-specific
information on type of treatment (RFA/EMR), resection hist-
ology, outcomes and adverse events. These data capture real-life
outcomes of high quality novel endoscopic therapy offered
within the confines of challenging service provision.
At endoscopy the BE segment was mapped and measured
using the Prague classification27 in centimetres. Enhanced endo-
scopic imaging techniques were used where available, such as
narrow band imaging (Olympus, Hamburg, Germany), i-scan
(Pentax, Hoya Corporation, Japan) and flexible spectral imaging
colour enhancement (FICE) (Fujinon, Saitama, Japan) to help
highlight potential dysplastic lesions for assessment and treat-
ment. All investigators used the Paris classification28 to classify
visible lesions. Endoscopic ultrasound was performed at the dis-
cretion of the operator if visible lesions were identified to
exclude T2 disease and mediastinal lymphadenopathy which
would preclude endoscopic therapy. The registry protocol man-
dated that EMR should be carried out for all visible lesions and
nodules where identified for therapeutic as well as staging pur-
poses. All nodularity was removed before RFA to the residual flat
BE segment. The BE mucosa was sampled using the Seattle 4
quadrant biopsy protocol.29 30 If invasive cancer was demon-
strated, patients were referred via their regional cancer MDT for
consideration of radical or palliative therapy.
A minimum of two endoscopies showing HGD or IMC was
mandatory prior to performing RFA. EMR could be carried out
at any time. Histology was reviewed by two expert gastrointes-
tinal histopathologists at the individual centres. The modified
Vienna classification31 was used to categorise pathological find-
ings before treatment decisions were made.
Registry endoscopy protocol
RFA was commenced with either the circumferential ablation
device (HALO 360) or with one of several focal RFA devices for
shorter non-circumferential areas of BE (HALO 90, HALO 60,
HALO ULTRA, Channel HALO device). The first RFA treatment
was deemed the start of the treatment protocol for all patients,
even after previous EMR. The treatment protocol is identical to
that used in our previous publications and has remained
unchanged over the two time periods being analysed here.24
The protocol has been designed to mirror the algorithm set out
in the first randomised controlled trial on RFA in patients with
BE neoplasia with the recommended end of protocol defined as
12 months at which stage patients were said to have completed
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treatment.23 In some patients with very short segments of BE
where clearance of disease was achieved sooner than the sug-
gested 12 months, the endpoint was the first endoscopy after
the completion of treatment where there was no neoplasia and
BE on biopsy.
The mean number of RFA sessions was 2–3 during the treat-
ment protocol in both time periods. All patients were main-
tained on omeprazole 40 mg twice daily or equivalent during
the treatment period. A flow chart of the registry protocol is
shown in figure 1.
Patients free of dysplasia or BE at end of protocol were
entered into a post-RFA surveillance protocol and were fol-
lowed up at 3-month intervals for the first year, 6-month inter-
vals for the second year and annually thereafter. Biopsies were
taken from 1 cm below the neo z-line and from the previously
treated BE segment using the Seattle protocol in line with the
BADCAT recommendation.32 Endoscopy with enhanced
imaging was advocated in all these cases to look for
recurrences.
In cases where there was residual dysplasia at the end of the
suggested treatment protocol, further endoscopic therapy was
offered with either RFA or EMR depending on the morphology
of the remaining neoplasia at endoscopy.
If biopsy-proven recurrence of dysplasia occurred after initial
successful therapy and was amenable to further RFA/EMR, this
was offered to the patient. Recurrence of intestinal metaplasia
(IM) after successful endoscopic eradication was judged to be a
true recurrence only when there was histological confirmation of
IM proximal to the neo-oesophagogastric junction (OGJ)
(>5 mm) in the previously treated BE segment. This mirrors
similar long-term follow-up studies where recurrence was defined
as IM in biopsies 3–10 mm above the neo-squamocolumnar junc-
tion (SCJ) at the gastro-oesophageal junction (GOJ).33 34
Following RFA, the biopsy protocol recommended samples
were taken above and below the neo-OGJ. Focal IM distal to
the neo-OGJ and from the gastric cardia was not deemed to be
true recurrence or criteria for retreatment. The presence of IM
in the gastric cardia or at the GOJ is a common pathological
finding at endoscopy and can occur in 5–18% of the normal
population.35 36 There is evidence that individuals with IM at
the cardia or GOJ have a significantly lower cancer risk than
patients with BE and therefore, if this was found on follow-up
biopsy, it was not re-treated.37
If the patients progressed to invasive disease at any time and
were no longer curable with endoscopic therapy, they were
referred back to the regional specialist MDT to discuss eligibility
for surgery or chemoradiotherapy. For patients who progressed
to invasive disease within the 12-month protocol period, data
were censored at their last procedure.
Clinical endpoints
The primary outcomes for the registry are clearance rate (CR) for
all dysplasia (CR-D), which was defined as no biopsy-proven
residual dysplasia of any grade in the previously treated Barrett’s
segment. Clearance of all BE (CR-IM) was defined by no evidence
of IM on biopsy at end of protocol from their index RFA treat-
ment. In addition, progression to invasive cancer and overall
cancer risk were observed in all patients in the registry. Long-term
outcomes and durability for reversal of dysplasia for those with a
favourable outcome at end of protocol were also assessed. Clinical
outcomes, patient demographics and treatment trends were then
analysed and compared between those who started treatment in
2008–2010 and those enrolled in 2011–2013.
Statistical considerations
Quantitative endpoints such as clearance of dysplasia at
12 months were compared with the patient’s baseline status
using Cox proportion hazard models, Student t tests and
Kaplan–Meier (KM) survival curves. Comparisons of outcome
measures between the two time periods were analysed with χ2
tests. Binomial logistic regression was performed on the entire
dataset and for each separate time period to assess the influence
of measured variables on the likelihood of achieving CR-D.
RESULTS
Registry enrollment and demographic data
Between 2008 and 2013 a total of 920 patients were treated in
the UK registry at 25 centres nationwide. Of these, 508 have
now completed treatment (266 patients in 2008–2010 and 242
patients in 2011–2013). Demographic data are shown in
table 1. There was no significant difference between the two
time periods with regard to patient age, number of RFA
Figure 1 UK radiofrequency ablation (RFA) registry protocol. The treatment protocol started following the first RFA treatment even in patients who
had had prior RFA. BE, Barrett’s oesophagus.
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treatment sessions or baseline length of BE being treated.
Baseline histology was not significantly different in both groups
between the two time periods. The majority of patients (overall
73%) were treated for HGD with the remainder being treated
for IMC, apart from 3% who were treated for low-grade dyspla-
sia. This has not changed over the 6-year period.
Thirty-eight per cent of patients were treated in the two largest
centres while the remaining cases were treated between the other
23 centres. In 2008–2010, 17 centres nationwide were providing
endoscopic therapy for BE-related neoplasia, contributing out-
comes to the registry. This had risen to 25 by 2013.
Patient outcomes 2008–2010
Between 2008 and 2010, 266 patients were treated and com-
pleted the treatment protocol. During this time, 12-month CR-D
was achieved in 77% of patients and reversal of IM (CR-IM) in
57% (table 2). Of these patients, 48% required EMR for visible
lesions before they underwent RFA and a further 13% needed
rescue EMR after the start of RFA treatment for new lesions.
Nine patients (3.6%) progressed to invasive cancer by 12 months
and a total of 18 (6.7%) of these patients have developed invasive
cancer at most recent follow-up (median follow-up 31 months
from end of treatment; range 3–72 months). KM survival ana-
lysis shows that at 5 years the estimated risk of progression to
cancer was 11% in this cohort (figure 2).
The logistic regression model identified that increasing age
(OR 1.04, 95% CI 1.004 to 1.078, p=0.03) and shorter lengths
of BE at baseline (OR 1.099, 95% CI 1.003 to 1.203, p=0.04)
were marginally more likely to achieve CR-D during this initial
time period. Conversely, rescue EMR during the treatment
protocol was associated with a reduction in the likelihood of
achieving CR-D in the initial treatment period (OR 0.4, 95% CI
0.176 to 0.907, p=0.028). Prior EMR and time to end of
protocol did not influence the outcomes.
Table 1 Comparison of demographic and pre-RFA characteristics for all patients undergoing endoscopic therapy for BE-related neoplasia
between 2008–2010 and 2011–2013
2008–2010 2011–2013 p Value
No of patients completing treatment protocol 266 242 NS
Mean age (range) 68 (40–87) 69 (44–90) NS
M:F (%) 80:20 84:16 NS
Baseline histology, n (%) NS
LGD 7 (3%) 7 (3%)
HGD 197 (74%) 172 (71%)
IMC 62 (23%) 63 (26%)
Previous photodynamic therapy (%) 9 3 0.02
Baseline BE length at start of RFA (maximum extent), cm 6 (1–20) 4.7 (1–16) NS
EMR prior to RFA, n (%) 128 (48%) 143 (60%) 0.016
Rescue EMR during RFA treatment, n (%) 35 (13%) 4 (2%) <0.0001
Mean time to end of protocol (months) 12.6 10.3 NS
Mean no of RFA treatments during treatment protocol 2.6 (1–5) 2.5 (1–5) NS
BE, Barrett’s oesophagus; EMR, endoscopic mucosal resection; HGD, high-grade dysplasia; IMC, intramucosal cancer; LGD, low-grade dysplasia; NS, not statistically significant; RFA,
radiofrequency ablation.
Table 2 Comparison of end of protocol treatment and long-term clinical outcomes for all patients undergoing endoscopic therapy for
BE-related neoplasia between 2008–2010 and 2011–2013
2008–2010 2011–2013 p Value
CR-IM at end of protocol in all patients 152/266 (57%) 201/242 (83%) <0.0001
CR-IM in patients with HGD 109/197 (55%) 145/172 (85%)
CR-IM in patients with IMC 38/62 (61%) 51/63 (81%)
CR-IM in patients with LGD 5/7 (71%) 5/7 (71%)
CR-D at end of protocol in all patients 206/266 (77%) 222/242 (92%) <0.0001
CR-D in patients with HGD 149/197 (76%) 159/172 (92%)
CR-D in patients with IMC 50/62 (81%) 57/62 (92%)
CR-D in patients with LGD 7/7 (100%) 6/7 (86%)
Progression to cancer at end of protocol 9/266 (3.4%) 5/242 (2.1%) 0.51
Progression to cancer at most recent follow-up 18/266 (6.7%) 6/242 (2.5%) Log rank 0.085
Median time to most recent biopsy from first treatment for those still in follow-up (months) 31 (3–72)
n=218
13 (2–32)
n=211
% free of dysplasia at most recent follow-up 97% 96% Log rank 0.2
% free of IM at most recent follow-up 91% 94% Log rank 0.02
Symptomatic stricture requiring endoscopic dilation 25/266 (9.4%) 15/242 (6.2%) 0.18
CR-D, complete reversal of dysplasia; CR-IM, complete reversal of intestinal metaplasia; HGD, high-grade dysplasia; IM, intestinal metaplasia; IMC, intramucosal cancer; LGD, low-grade
dysplasia; NS, not statistically significant.
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Patient outcomes 2011–2013
In the time period 2011–2013 a further 242 patients were
treated and 12-month biopsy results were available. There was a
significant improvement in outcomes with 92% CR-D and 83%
CR-IM (p<0.0001) compared with patients treated in 2007–
2010 (figure 3). Furthermore, the use of EMR prior to RFA
increased to 60% (p=0.016). Conversely, the requirement for
rescue EMR after the start of RFA treatment was reduced from
13% to only 2% (p<0.0001). In 2011–2013 the progression to
invasive cancer at 12 months was 2.1% and this did not change
(p=0.51). For this group, the KM calculated cancer risk at
almost 34 months was 3% (figure 3). Taking into consideration
the fact that the follow-up periods in these two groups were dif-
ferent, there is currently no overall statistical significance in
long-term cancer progression (log rank p=0.85).
The logistic regression model found that the previously sig-
nificant influence of age, initial length of BE and rescue EMR
on achieving CR-D did not remain in this period. No other vari-
ables were found to influence outcomes significantly.
When the logistic regression model was applied to the entire
dataset for 2008–2013, increasing age (OR 1.316, 95% CI
0.685 to 2.529), prior EMR (OR 1.358, 95% CI 0.776 to
2.337) and shorter lengths of BE at baseline (OR 1.103, 95%
CI 1.023 to 1.190) were more likely to achieve CR-D. Again,
rescue EMR (OR 0.426, 95% CI 0.195 to 0.930) reduced the
chances of successful treatment.
Despite the increased use of EMR latterly, the risk of symp-
tomatic stenosis requiring endoscopic therapy did not change
significantly over time (9.4% in 2007–2010 vs 6.2% in 2011–
2013, p=0.18; table 2).
There was a single perforation in the very early experience of
the study with a 34 mm ablation balloon that is now no longer
available. The patient made a full recovery and went on to
achieve disease clearance. The rate of bleeding was <1% in
both time periods, none of which required blood transfusion.
Durability of response
Long-term durability of neoplasia reversal was assessed in these
two cohorts using KM survival statistics. This demonstrated
that, in the earlier time period, the risk of neoplasia recurrence
was in the region of 19% at 5 years. Taking into account the
shorter follow-up period in patients treated more recently, the
risk of recurrence at 26 months was 7%. These data are not stat-
istically significant (log rank p=0.2, figure 4).
With respect to reversal of IM over the two time periods, the
predicted risk of IM recurrence was 13% at 26 months in
patients treated in the most recent time period. At the same
time period the predicted IM recurrence was 12% in patients
treated between 2008 and 2010. At 5 years there is a 32% risk
of IM recurrence in this cohort of patients. It appears from KM
statistics (figure 5) that the majority of IM recurrences in
patients treated more recently tend to occur within the first
12 months after treatment, following which this risk plateaus.
Outcomes of cancer patients
A total of 24 patients progressed to invasive disease that was no
longer amenable to endoscopic therapy. Ten of these 24 patients
Figure 2 Graph showing improvement in complete reversal of
intestinal metaplasia (CR-IM) and complete reversal of dysplasia (CR-D)
in patients undergoing radiofrequency ablation/endoscopic mucosal
resection between 2008–2010 and 2011–2013.
Figure 4 Kaplan–Meier survival statistics showing durability of
neoplasia reversal in patients treated within the two time periods.
Figure 3 Kaplan–Meier analysis demonstrating estimated cancer
progression from start of treatment in patients undergoing endoscopic
therapy for Barrett’s oesophagus-related neoplasia over the two time
periods.
Figure 5 Kaplan–Meier survival statistics showing durability of intestinal
metaplasia reversal in patients treated within the two time periods.
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were treated with oesophagectomy, one of whom died intrao-
peratively. Two patients presented with metastatic disease; one
was lost to follow-up and the remaining 11 patients had locally
advanced disease that was treated with palliative therapy ranging
from chemoradiotherapy or endoscopic laser therapy for
obstructive symptoms.
DISCUSSION
There is now consensus that first-line treatment for mucosal
neoplasia arising in BE should be endoscopic therapy.18
Following the first randomised controlled trial demonstrating
efficacy and safety of RFA in carefully selected patients with
low-grade dysplasia (LGD) and HGD,23 there have been numer-
ous further large-volume multicentre prospective series demon-
strating similar rates of efficacy worldwide.24 25 34 38 Surgical
outcomes for those undergoing oesophagectomy have also
improved and, for those with more advanced neoplasia infiltrat-
ing the submucosa and beyond, this should be considered if
there is no distant spread. Recent guidelines from the BSG
endorse this management.18
Our data demonstrate that clinical outcomes for patients with
mucosal BE neoplasia undergoing endoscopic therapy have
improved since 2008. Furthermore, the practice of EMR being
more widely used prior to initiating RFA may explain the
improved outcomes. The manner in which the registry data are
collated does not capture the extent of EMR before RFA and
whether this changed over time. One could argue that, if larger
areas were resected at baseline in the later time period, this
would leave less residual BE which would require fewer RFA
treatment sessions. The higher proportion of patients undergo-
ing EMR may therefore account for the observed difference,
although the number of RFA sessions did not actually fall in the
second time period.
An alternative explanation from our data is that EMR eradi-
cated the visible and nodular neoplasia, making treatment more
successful in the latter time period. In our opinion, lesion recog-
nition and resection are paramount to successful outcomes in
patients with BE neoplasia. Visible and nodular lesions are more
likely to harbour more advanced neoplasia, so early resection is
key to both definitive staging and eradication prior to possible
RFA. However, despite the known efficacy of combined RFA
and EMR for these patients, treatment can be limited by the
ability to find the areas that need to be treated. The accurate
detection of neoplasia is an important objective that incorpo-
rates both new technologies in endoscopic imaging and continu-
ing understanding of recognising abnormalities of the mucosa
and microvasculature by the endoscopist.
Endoscopic imaging has dramatically improved over the past
5 years, allowing endoscopists to assess mucosal anomalies in
detail and enabling accurate sampling of suspected areas of neo-
plasia and direct therapy. White light endoscopy alone, with
random sampling of the tubular oesosphagus, can often over-
look lesions that require resection. High-resolution video endo-
scopes with high-quality charge-coupled device chips (up to 1.2
million pixels) allow inspection of minute details of the mucosal
and vascular architecture that were not readily visible with pre-
viously used white light endoscopes. High-definition endoscopy
with various imaging enhancements is now practised at most
high-volume centres performing therapy for BE neoplasia.
There are increasing data to support improved diagnostic yield
with enhanced imaging. In 2012 Sharma et al compared narrow
band imaging (NBI) with standard high-definition white light
endoscopy (HD-WLE) to detect IM and neoplasia in patients
undergoing BE assessment and found that neoplasia detection
was higher with NBI than with HD-WLE (30% vs 21%,
p=0.01).39 Pohl et al40 demonstrated that, by targeting biopsies
with HD-WLE and image enhancement, the sensitivity and spe-
cificity rates for BE neoplasia were 96.7% and 66.5%,
respectively.
The use of chromoendoscopy as an adjunct to enhanced
imaging technology and high-definition endoscopy has become
more widespread and allows more accurate diagnosis of neopla-
sia. Several studies have shown that the use of acetic acid in
patients with BE can improve neoplasia yield.41
Improved lesion recognition with advancements in endo-
scopic technology and training of endoscopists has led to more
aggressive and widespread use of EMR prior to RFA. The more
widespread use of EMR in the past 3 years of the registry has,
in our opinion, led to improved clinical outcomes and can be
seen to provide two potential benefits. First, it serves as a larger
and deeper biopsy specimen, allowing more precise determin-
ation of the depth of tumour penetration than any other
method currently available. Most specimens contain significant
portions of the submucosa, allowing differentiation of mucosal
from submucosal tumours. EMR has been shown to have
improved sensitivity over endoscopic ultrasound for differentiat-
ing submucosal involvement in patients with BE neoplasia.42
Submucosal involvement in patients with visible lesions carries a
significant risk of lymph node metastasis at 5 years. Those with
neoplasia confined to the superficial 500 μm of the submucosa
(T1b, SM1 disease) still have a rate of lymph node metastases of
1–4% at 5 years.43 With increased use of EMR before RFA,
patients with submucosal disease can be filtered out and offered
surgery rather than further endotherapy with curative intent as
they are less likely to have a favourable outcome. Second, it can
be performed with curative intent for visible lesions allowing
for RFA of the residual flat BE segment. Indeed, EMR has been
shown to be very effective alone in the treatment of BE-related
neoplasia44 as well as when combined with RFA. Within the
registry the increased use of EMR prior to RFA in the past
3 years has seen a dramatic fall in the need for rescue EMR.
One could postulate that the limited use of EMR in the first
3 years of the registry experience meant that more patients
needed rescue EMR, and this corresponded to the less impres-
sive clinical outcomes.
While improved endoscopic imaging and more EMR could
explain the improved outcomes, other parameters may have also
contributed. These include increased physician awareness,
improved disease staging, better patient selection and improved
endoscopic skills in this novel area of therapeutics. Over the
next few years it is conceivable that long-term outcomes for
these high-risk patients may improve further.
Recent publications have explored predictors of successful
RFA treatment and predictors of disease recurrence. Van
Vilsteren et al45 identified four predictive factors for a poor
initial response after circumferential RFA at 3 months. These
were active reflux oesophagitis, regeneration of BE over the site
of a previous endoscopic resection, pre-existing oesophageal
narrowing before RFA and the number of years of neoplasia
pre-RFA. Pasricha et al showed from the US RFA registry that
more advanced pretreatment histology was associated with an
increased recurrence rate. They also demonstrated that patients
with recurrence were more likely to be older, have longer BE
segments, be non-Caucasian, have dysplastic BE before treat-
ment and require more treatment sessions.26
We have shown in our previous data that CR-D was 15% less
likely for every 1 cm increment in BE length (OR 1.156; SE
0.048; 95% CI 1.07 to 1.26; p<0.001).24 In our current series
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the BE length was marginally shorter in the later time period
(4.7 cm in 2011–2013 vs 6.0 cm in 2008–2010) and may also
therefore have been a contributing factor to the improved
disease reversal rates observed.
Overall progression to invasive disease in patients with BE is
quoted to be in the region of 0.12–0.40% per annum.5–7 In our
registry data the rate of progression in all patients undergoing
endoscopic therapy for BE-related neoplasia fell to 2.1% at
12 months in the past 3 years compared with 3.4% in the initial
time period. The durability of cancer-free survival between the
two groups does not appear to be significantly different.
However, the follow-up periods are different. These patients are
biologically at high risk despite endoscopic intervention. It
remains to be seen whether the better reversal rates of dysplasia
translate into a long-term reduction in cancer incidence.
Combined RFA and EMR for carefully selected patients with
BE neoplasia is now an established alternative to more invasive
surgery. Most importantly, as experience accumulates over time
with improved endoscopic imaging and therapeutic skill levels,
the clinical outcome for these patients continues to improve.
While the advantages of a less invasive approach to treatment
for BE neoplasia are appealing, less obvious is the anxiety to the
patient that comes with the need for repeated endoscopic inter-
ventions compared with surgery. Surgical resection remains a
viable option for those with disease extending beyond the
mucosa and may also remain appropriate for those with early
disease who choose not to have multiple endoscopies.
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